Days after announcing record losses, drug developer Summit has sealed a licensing deal worth up to $143m (£72m) for one of its pre-clinical candidates.
This is an important deal for Summit, known until last year as VASTox, whose valuation halved in the last two years as the market began to doubt its original assessment. Recent results cast the shares even lower as the Oxfordshire-based company unveiled losses had trebled in the year to January as it geared up R&D.
However Summit’s model is an interesting one as it has two technology platforms, zebrafish and carbohydrate chemistry, that both perform the similar dual function of generating cash as service providers and enabling the company to discover its own drugs. Thus there are five drug candidates on the roster, three at the pre-clinical stage and two in clinical trials.
After signing a £10m collaboration last year with Swiss company Evolva for a treatment that emerged from its carbohydrate chemistry platform, Summit’s has now secured a much bigger deal. US biopharma Bi0Marin has bought the worldwide licence to develop and commercialise the compound C1100 for the treatment of Duchenne’s muscular dystrophy for $143m.
This involves an immediate $7m equity investment and, says Summit’s chief executive Steve Lee, ‘by early next year we could trigger $4m with another $50m in the next three years at no extra cost to us.’ With BioMarin absorbing some development costs, house broker Panmure predicts R&D spend in each of the next two years will be £2m lower.
With £10m cash in the bank at year end and the management’s strategy proven, Lee’s hopes to sign deals for other drugs or even a collaboration on the entire carbohydrates platform have gained weight. Less than half their 135p listing price, the shares look unfairly undervalued. Speculative buy.
Market cap: £32.03m
PE Forecast: n/a
Share price: 63p
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
M&A on AIM 2009 is a unique and wide-ranging examination of merger and acquisition activity on AIM over the past 12 months, with an analysis of all the acquisitions, disposals, takeovers and delistings on AIM, including
canvassing the opinions of some of the major M&A powerbrokers. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Energy industry consultant KBC performed resiliently in recession-hit 2009 and entered 2010 with a robust order book.
Organic composting specialist TEG is pursuing long-term contracts after turning £1.6m of annual losses into £155,000 pre-tax profits in calendar 2009.
European Goldfields hopes to move from AIM to the Full List by the end of 2010 after securing a key permit in Romania.